Advertisement

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Opening Session Panel Discussion

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Varsha Gandhi, PhD, on Ibrutinib

Opportunities to Optimize Cancer Policies Panel Discussion

Advertisement

Advertisement

Jan

14

Today In Oncology

WGS-Based Classifier Better Predicts HRD Across Cancer Types

ACS Report Shows 5-Year Survival Rate for All Cancers Combined Has Reached 70%

Can DNA Testing of Colorectal Polyps Improve Insight Into Genetic Risks

Pirtobrutinib vs Ibrutinib in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Multiple Myeloma Sex Differences in Etiology and Clinical Presentation

Advertisement

© 2026 HSP News Service, L.L.C.